Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bausch HealthBHC -2.03%58 EV-to-EBITDA is 11.50 as of Jul. 19, 2026, which is 1% below its 10-year median of 11.66. GuruFocus rates BHC with a GF Score™ of 58/100 and a GF Value™ of $7.93 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 741 Drug Manufacturers companies, Bausch Health ranks better than 53.71% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bausch Health's enterprise value is $22,234 Mil.
Bausch Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $1,934 Mil. Therefore, Bausch Health's EV-to-EBITDA for today is 11.50.
The historical rank and industry rank for Bausch Health's EV-to-EBITDA or its related term are showing as below:
BHC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.9 Med: 11.66 Max: 191.49
Current: 11.84
During the past 13 years, the highest EV-to-EBITDA of Bausch Health was 191.49. The lowest was 6.90. And the median was 11.66.
BHC's EV-to-EBITDA is ranked better than 53.71% of 741
companies
in the Drug Manufacturers industry
Industry Median: 13.01
vs BHC: 11.84
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Bausch Health (NYSE:BHC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bausch Health's PE Ratio (TTM) for today is calculated as:
Bausch Health's share price for today is $4.83.
Bausch Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bausch Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch Health EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bausch Health's EV-to-EBITDA falls into.
Bausch Health's current Enterprise Value is $22,234 Mil.
Bausch Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,934 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch Health (BHC) has a EV-to-EBITDA of 11.50 as of Jul. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bausch Health. This is near median its historical median of 11.66. Over the past decade, Bausch Health's EV-to-EBITDA has ranged from 6.90 to 191.49. According to the industry distribution chart, Bausch Health ranks #343 out of 741 companies in the Drug Manufacturers industry, placing it in the top 46.3%.
Is Bausch Health's EV-to-EBITDA too high?
Bausch Health's current EV-to-EBITDA of 11.50 is near median its 10-year median of 11.66. Over the past 10 years, this metric has ranged from a low of 6.90 to a high of 191.49. The Drug Manufacturers industry median EV-to-EBITDA is 13.01. Bausch Health's value of 11.50 is 11.6% below this industry median. Based on the distribution chart, Bausch Health ranks #343 out of 741 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bausch Health has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #343 out of 741 companies for EV-to-EBITDA. This puts Bausch Health in the upper half of its industry. The industry median EV-to-EBITDA is 13.01. Bausch Health's value of 11.50 is 11.6% below this benchmark. Historically, Bausch Health's own EV-to-EBITDA has ranged from 6.90 to 191.49 over the past decade. While the company's 10-year median is 11.66 vs. the industry median of 13.01, Bausch Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.01, based on 741 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch Health's current EV-to-EBITDA of 11.50 is 11.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bausch Health. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch Health's current EV-to-EBITDA is 11.50, which is near median its own 10-year median of 11.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (BHC) is currently considered Possible Value Trap. The stock's GF Value™ is $7.93, compared to a current price of $4.83 — trading 39.1% below its estimated fair value. The current EV-to-EBITDA is 11.50, which is near median its 10-year median of 11.66 and 11.6% below the Drug Manufacturers industry median of 13.01. Bausch Health's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bausch Health (BHC), the current EV-to-EBITDA is 11.50 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch Health (BHC) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued.
The current stock price of $4.83 is trading 39.1% below its estimated GF Value™ of $7.93.
GuruFocus considers Bausch Health to be Possible Value Trap.
Key valuation signals for BHC:
EV-to-EBITDA: 11.50 (near median its 10-year median of 11.66)
GF Value™: $7.93 vs. price of $4.83 (39.1% below fair value)
Industry Position: 11.6% below the Drug Manufacturers median (#343 of 741)
No single metric tells the full story. See the BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
58GF Score
Get the complete analysis for BHC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHC has been successfully added to your 
